

June 21, 2024

To: The Office of the Attorney General of Vermont

Via: Electronic Mail (AGO.DrugCosts@vermont.gov; AGO.highcostprescriptiondrugs@vermont.gov)

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637 (c)

On May 22, 2024 and pursuant to 18 V.S.A. § 4637 (b), Amgen Inc, USA (Amgen) submitted a notice of new drug introduction for the following:

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC
Imdelltra™ (1 mg vial)	55513-059-01	5/22/2024	\$1,500.00
Imdelltra™ (10 mg vial)	55513-077-01	5/22/2024	\$15,000.00

Amgen now provides the following additional information pursuant to 18 V.S.A § 4637 (c):

1. United States and international marketing and pricing plans used at launch:

- There is a direct-to-consumer marketing plan for IMDELLTRA. Efforts in the public domain currently consist of: (1) patient website www.IMDELLTRA.com & search and (2) patient educational brochure & wallet card. The purpose of the website is to educate patients about small cell lung cancer (SCLC) and IMDELLTRA aligned to the IMDELLTRA USPI, including Important Safety Information. It also provides information about Amgen SupportPlus and the Amgen Patient Navigator program. The Amgen SupportPlus Co-Pay Program may help eligible patients with private or commercial insurance lower their out-of-pocket costs.
- Promotional activities to HCPs include the HCP website, www.imdelltrahcp.com, search, banner ads, email blasts, and other print, digital, and Peer to Peer resources and programs in line with the IMDELLTRA USPI. The purpose of these tools is to build awareness of a new treatment and for education, as IMDELLTRA is the first and only BiTE(R) therapy approved for 2L+ Extensive-Stage Small Cell Lung Cancer. Through Amgen SupportPlus, IMDELLTRA offers Patient Navigator to patients and providers as single point of contact to support access and navigating treatment logistics.
- Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
 - i. Pricing our products according to the value they deliver
 - ii. Employs flexible pricing approaches to ensure patient access

2. Estimate Volume of Patients:
 - Amgen provides this report with its understanding of 18 V.S.A. §4637(d) and reserves all of its rights thereunder and otherwise.

3. Whether the FDA granted breakthrough therapy designation or priority review:
 - Imdelltra was granted both breakthrough therapy designation and priority review by the FDA

4. Date and price of acquisition:
 - Not Applicable

Amgen provides this report consistent with its understanding and interpretation of 18 V.S.A § 4637 and its provisions. In providing this report, Amgen does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Amgen or any of its affiliates, now or in the future. Amgen, on behalf of itself and its affiliates, expressly reserves all such rights.

Regards,

Pat Costello

Executive Director, US Value and Access Strategy

Amgen Inc, USA